EQ-101 is under clinical development by Equillium and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect EQ-101’s likelihood of approval (LoA) and phase transition for Cutaneous T-Cell Lymphoma took place on 08 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their EQ-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

EQ-101 overview

EQ-101 is under development for the treatment of T-cell leukemias including large granular leukemia (LGL), refractory cutaneous T-cell lymphoma (CTCL) and alopecia areata. It is a PEGylated 24-amino acid peptide inhibitor of Interleukin-2, Interleukin-9 and Interleukin-15 and administered through intravenous and subcutaneous routes. It is developed based on bioniz technology. The drug candidate was also under development for the treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM-TSP). 

Equillium overview

Equillium formerly Attenuate Biopharmaceuticals Inc, is a biotechnology company specialized on immunobiology to develop medicines for the treatment of autoimmune and inflammatory disorders. The company’s pipeline product include EQ001 (itolizumab), a first-in-class monoclonal antibody that targets the novel immune checkpoint receptor CD6 that inhibits pathogenic cellular pathways for effector T cell development. Equillium develops its products for immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company has collaboration with Biocon Ltd, for licensing opportunities of its pipeline product. Equillium is headquartered in California, the US.

Quick View EQ-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • EQ-101
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Oncology
Key Developers
  • Sponsor Company: Equillium
  • Originator: Bioniz Therapeutics
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.